Zydus and CMS enter pact for Desidustat in Greater China
The agreement is for Desidustat, a novel oral HIF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CMS
SPARC enters into licensing deal with CMS to develop and commercialise products
The initial term of the agreement shall be 20 years from the date of first commercial sale of each product in the territory and…
Biocon licenses three generic formulation products to China Medical System Holdings
Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products…
Sun Pharma and CMS enter into a License Agreement for Cyclosporine A and Tildrakizumab in Greater…
Under the terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone…